69907-68-2Relevant articles and documents
Linker, Antibody-Drug Conjugate Including Same and Use Thereof
-
Paragraph 0447; 0448, (2021/08/27)
Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.
In situ formation of N-trifluoroacetoxy succinimide (TFA-NHS): One-pot formation of succinimidyl esters, N-trifluoroacetyl amino acid succinimidyl esters, and N-maleoyl amino acid succinimidyl esters
Leonard, Nicholas M.,Brunckova, Jarmila
supporting information; experimental part, p. 9169 - 9174 (2011/12/16)
A method for the in situ formation of N-trifluoroacetoxy succinimide (TFA-NHS) and its application in the formation of succinimidyl esters is presented. The developed method provides N-trifluoroacetyl and N-maleoyl amino acid succinimidyl esters from a variety of amino acids using a one-pot, high-yielding protocol. Investigations into the formation of an N-maleoyl amino acid succinimidyl ester supported the proposal of a revised reaction mechanism, and contributed to the optimization of the reaction conditions.
N-(3-Triethoxysilylpropyl)-4-(N′-maleimidylmethyl)cyclohexanamide (TPMC): A heterobifunctional reagent for immobilization of oligonucleotides on glass surface
Misra, Arvind
, p. 3749 - 3753 (2008/02/10)
A new heterobifunctional reagent, namely, N-(3-triethoxysilylpropyl)-4-(N′-maleimidylmethyl)cyclohexanamide (TPMC) was developed and its potentiality for fixing of thiol (-SH) modified oligonucleotides were tested. The covalent attachment of oligonucleoti